Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder

S D Kaupp-Roberts; G Yadegarfar; E Friend; C M O'Donnell; J W Valle; C Byrne; I Bahar; M Finch-Jones; R Gillmore; C D Johnson; S P Pereira; J K Wiggers; M Pinto; B Al-Sarireh; J K Ramage

doi:10.1038/bjc.2016.284

Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder

S D Kaupp-Roberts, G Yadegarfar, E Friend, C M O'Donnell, J W Valle, C Byrne, I Bahar, M Finch-Jones, R Gillmore, C D Johnson, S P Pereira, J K Wiggers, M Pinto, B Al-Sarireh, J K Ramage

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: There is no specific quality of life (QoL) measurement tool to quantify QoL in patients with biliary tract cancer. Quality of life measurement is an increasingly crucial trial end point and is now being incorporated into clinical practice.

METHODS: This International Multicentre Phase IV Validation Study assessed the QLQ-BIL21 module in 172 patients with cholangiocarcinoma and 91 patients with cancer of the gallbladder. Patients completed the questionnaire at baseline pretherapy and subsequently at 2 months. Following this, the psychometric properties of reliability, validity, scale structure and responsiveness to change were analysed.

RESULTS: Analysis of the QLQ-BIL21 scales showed appropriate reliability with Cronbach's α-coefficients >0.70 for all scales overall. Intraclass correlations exceeded 0.80 for all scales. Convergent validity >0.40 was demonstrated for all items within scales, and discriminant validity was confirmed with values <0.70 for all scales compared with each other. Scale scores changed in accordance with Karnofsky performance status and in response to clinical change.

CONCLUSIONS: The QLQ-BIL21 is a valid tool for the assessment of QoL in patients with cholangiocarcinoma and cancer of the gallbladder.

Original language	English
Pages (from-to)	1032-1038
Number of pages	7
Journal	British Journal of Cancer
Volume	115
Issue number	9
DOIs	https://doi.org/10.1038/bjc.2016.284
Publication status	Published - 25 Oct 2016

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2016.284

Cite this

Kaupp-Roberts, S. D., Yadegarfar, G., Friend, E., O'Donnell, C. M., Valle, J. W., Byrne, C., Bahar, I., Finch-Jones, M., Gillmore, R., Johnson, C. D., Pereira, S. P., Wiggers, J. K., Pinto, M., Al-Sarireh, B., & Ramage, J. K. (2016). Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. British Journal of Cancer, 115(9), 1032-1038. https://doi.org/10.1038/bjc.2016.284

@article{24d363c11e514dca887631f66a638ff5,

title = "Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder",

abstract = "BACKGROUND: There is no specific quality of life (QoL) measurement tool to quantify QoL in patients with biliary tract cancer. Quality of life measurement is an increasingly crucial trial end point and is now being incorporated into clinical practice.METHODS: This International Multicentre Phase IV Validation Study assessed the QLQ-BIL21 module in 172 patients with cholangiocarcinoma and 91 patients with cancer of the gallbladder. Patients completed the questionnaire at baseline pretherapy and subsequently at 2 months. Following this, the psychometric properties of reliability, validity, scale structure and responsiveness to change were analysed.RESULTS: Analysis of the QLQ-BIL21 scales showed appropriate reliability with Cronbach's α-coefficients >0.70 for all scales overall. Intraclass correlations exceeded 0.80 for all scales. Convergent validity >0.40 was demonstrated for all items within scales, and discriminant validity was confirmed with values <0.70 for all scales compared with each other. Scale scores changed in accordance with Karnofsky performance status and in response to clinical change.CONCLUSIONS: The QLQ-BIL21 is a valid tool for the assessment of QoL in patients with cholangiocarcinoma and cancer of the gallbladder.",

author = "Kaupp-Roberts, {S D} and G Yadegarfar and E Friend and O'Donnell, {C M} and Valle, {J W} and C Byrne and I Bahar and M Finch-Jones and R Gillmore and Johnson, {C D} and Pereira, {S P} and Wiggers, {J K} and M Pinto and B Al-Sarireh and Ramage, {J K}",

year = "2016",

month = oct,

day = "25",

doi = "10.1038/bjc.2016.284",

language = "English",

volume = "115",

pages = "1032--1038",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "9",

}

Kaupp-Roberts, SD, Yadegarfar, G, Friend, E, O'Donnell, CM, Valle, JW, Byrne, C, Bahar, I, Finch-Jones, M, Gillmore, R, Johnson, CD, Pereira, SP, Wiggers, JK, Pinto, M, Al-Sarireh, B & Ramage, JK 2016, 'Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder', British Journal of Cancer, vol. 115, no. 9, pp. 1032-1038. https://doi.org/10.1038/bjc.2016.284

TY - JOUR

T1 - Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder

AU - Kaupp-Roberts, S D

AU - Yadegarfar, G

AU - Friend, E

AU - O'Donnell, C M

AU - Valle, J W

AU - Byrne, C

AU - Bahar, I

AU - Finch-Jones, M

AU - Gillmore, R

AU - Johnson, C D

AU - Pereira, S P

AU - Wiggers, J K

AU - Pinto, M

AU - Al-Sarireh, B

AU - Ramage, J K

PY - 2016/10/25

Y1 - 2016/10/25

N2 - BACKGROUND: There is no specific quality of life (QoL) measurement tool to quantify QoL in patients with biliary tract cancer. Quality of life measurement is an increasingly crucial trial end point and is now being incorporated into clinical practice.METHODS: This International Multicentre Phase IV Validation Study assessed the QLQ-BIL21 module in 172 patients with cholangiocarcinoma and 91 patients with cancer of the gallbladder. Patients completed the questionnaire at baseline pretherapy and subsequently at 2 months. Following this, the psychometric properties of reliability, validity, scale structure and responsiveness to change were analysed.RESULTS: Analysis of the QLQ-BIL21 scales showed appropriate reliability with Cronbach's α-coefficients >0.70 for all scales overall. Intraclass correlations exceeded 0.80 for all scales. Convergent validity >0.40 was demonstrated for all items within scales, and discriminant validity was confirmed with values <0.70 for all scales compared with each other. Scale scores changed in accordance with Karnofsky performance status and in response to clinical change.CONCLUSIONS: The QLQ-BIL21 is a valid tool for the assessment of QoL in patients with cholangiocarcinoma and cancer of the gallbladder.

AB - BACKGROUND: There is no specific quality of life (QoL) measurement tool to quantify QoL in patients with biliary tract cancer. Quality of life measurement is an increasingly crucial trial end point and is now being incorporated into clinical practice.METHODS: This International Multicentre Phase IV Validation Study assessed the QLQ-BIL21 module in 172 patients with cholangiocarcinoma and 91 patients with cancer of the gallbladder. Patients completed the questionnaire at baseline pretherapy and subsequently at 2 months. Following this, the psychometric properties of reliability, validity, scale structure and responsiveness to change were analysed.RESULTS: Analysis of the QLQ-BIL21 scales showed appropriate reliability with Cronbach's α-coefficients >0.70 for all scales overall. Intraclass correlations exceeded 0.80 for all scales. Convergent validity >0.40 was demonstrated for all items within scales, and discriminant validity was confirmed with values <0.70 for all scales compared with each other. Scale scores changed in accordance with Karnofsky performance status and in response to clinical change.CONCLUSIONS: The QLQ-BIL21 is a valid tool for the assessment of QoL in patients with cholangiocarcinoma and cancer of the gallbladder.

U2 - 10.1038/bjc.2016.284

DO - 10.1038/bjc.2016.284

M3 - Article

C2 - 27673364

SN - 0007-0920

VL - 115

SP - 1032

EP - 1038

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 9

ER -

Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder

Abstract

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this